{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:07:31Z","timestamp":1784635651020,"version":"3.55.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,30]]},"abstract":"<jats:p>Recombinant human high-dose IL2 (HD-IL2; aldesleukin) was one of the first approved immune-oncology agents based upon clinical activity in renal cell carcinoma (RCC) and metastatic melanoma but use was limited due to severe toxicity. Next-generation IL2 agents designed to improve tolerability are in development, increasing the need for future identification of genomic markers of clinical benefit and\/or clinical response. In this retrospective study, we report clinical and tumor molecular profiling from patients with metastatic RCC (mRCC) treated with HD-IL2 and compare findings with patients with RCC treated with anti-PD-1 therapy. Genomic characteristics common and unique to IL2 and\/or anti-PD-1 therapy response are presented, with insight into rational combination strategies for these agents.<\/jats:p>\n                  <jats:p>Residual pretreatment formalin-fixed paraffin embedded tumor samples from n = 36 patients with HD-IL2 mRCC underwent RNA-sequencing and corresponding clinical data were collected. A de novo 40-gene nearest centroid IL2 treatment response classifier and individual gene and\/or immune marker signature differences were correlated to clinical response and placed into context with a separate dataset of n = 35 patients with anti-PD-1 mRCC.<\/jats:p>\n                  <jats:p>Immune signatures and genes, comprising suppressor and effector cells, were increased in patients with HD-IL2 clinical benefit. The 40-gene response classifier was also highly enriched for immune genes. While several effector immune signatures and genes were common between IL2 and anti-PD-1 treated patients, multiple inflammatory and\/or immunosuppressive genes, previously reported to predict poor response to anti-PD-L1 immunotherapy, were only increased in IL2\u2013responsive tumors.<\/jats:p>\n                  <jats:p>These findings suggest that common and distinct immune-related response markers for IL2 and anti-PD-1 therapy may help guide their use, either alone or in combination.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Next-generation IL2 agents, designed for improved tolerability over traditional HD-IL2 (aldesleukin), are in clinical development. Retrospective molecular tumor profiling of patients treated with HD-IL2 or anti-PD-1 therapy provides insights into genomic characteristics of therapy response. This study revealed common and distinct immune-related predictive response markers for IL2 and anti-PD-1 therapy which may play a role in therapy guidance, and rational combination strategies for these agents.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-21-0153","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T09:04:52Z","timestamp":1658739892000},"page":"894-903","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1009-2776","authenticated-orcid":true,"given":"Joel R.","family":"Eisner","sequence":"first","affiliation":[{"name":"1GeneCentric Therapeutics, Inc., Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5799-1608","authenticated-orcid":true,"given":"Kirk D.","family":"Beebe","sequence":"additional","affiliation":[{"name":"1GeneCentric Therapeutics, Inc., Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory M.","family":"Mayhew","sequence":"additional","affiliation":[{"name":"1GeneCentric Therapeutics, Inc., Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Shibata","sequence":"additional","affiliation":[{"name":"1GeneCentric Therapeutics, Inc., Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1287-1906","authenticated-orcid":true,"given":"Yuelong","family":"Guo","sequence":"additional","affiliation":[{"name":"1GeneCentric Therapeutics, Inc., Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9189-983X","authenticated-orcid":true,"given":"Carol","family":"Farhangfar","sequence":"additional","affiliation":[{"name":"2Levine Cancer Institute, Atrium Health, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhang","family":"Farhangfar","sequence":"additional","affiliation":[{"name":"2Levine Cancer Institute, Atrium Health, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Uronis","sequence":"additional","affiliation":[{"name":"1GeneCentric Therapeutics, Inc., Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Mooney","sequence":"additional","affiliation":[{"name":"3Synthorx, Inc \u2013 A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Milburn","sequence":"additional","affiliation":[{"name":"1GeneCentric Therapeutics, Inc., Durham, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-8356","authenticated-orcid":true,"given":"David","family":"Foureau","sequence":"additional","affiliation":[{"name":"2Levine Cancer Institute, Atrium Health, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"White","sequence":"additional","affiliation":[{"name":"2Levine Cancer Institute, Atrium Health, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Amin","sequence":"additional","affiliation":[{"name":"2Levine Cancer Institute, Atrium Health, Charlotte, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos E.","family":"Milla","sequence":"additional","affiliation":[{"name":"3Synthorx, Inc \u2013 A Sanofi Company, La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1126\/science.181845","article-title":"Selective in vitro growth of T lymphocytes from normal human bone marrows","volume":"193","author":"Morgan","year":"1976","journal-title":"Science"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1084\/jem.157.3.884","article-title":"Lymphokine-activated killer cell phenomenon II.: Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells","volume":"157","author":"Grimm","year":"1983","journal-title":"J Exp Med"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.6367046","article-title":"Biological activity of recombinant human interleukin-2 produced in Escherichia coli","volume":"223","author":"Rosenberg","year":"1984","journal-title":"Science"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2051-1426-2-13","article-title":"Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program","volume":"2","author":"Payne","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"74","DOI":"10.15586\/jkcvhl.2014.18","article-title":"Interleukin-2 in renal cell carcinoma: a has-been or a still-viable option?","volume":"1","author":"Amin","year":"2014","journal-title":"J Kidney Cancer VHL"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.1158\/1078-0432.CCR-11-1650","article-title":"Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma","volume":"17","author":"Weiss","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: emerging targets and combination therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front Oncol"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/d41573-021-00034-6","article-title":"Restoring IL-2 to its cancer immunotherapy glory","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","article-title":"Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: phase I dose-escalation study of safety, efficacy, and immune activation (PIVOT-02)","volume":"10","author":"Diab","year":"2020","journal-title":"Cancer Discov"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"e1277306","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"e000673","DOI":"10.1136\/jitc-2020-000673","article-title":"ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy","volume":"8","author":"Lopes","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1038\/s41467-021-24987-9","article-title":"An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism","volume":"12","author":"Ptacin","year":"2021","journal-title":"Nat Commun"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s00262-018-2152-x","article-title":"Quantitative T-cell repertoire analysis of peripheral blood mononuclear cells from lung cancer patients following long-term cancer peptide vaccination","volume":"67","author":"Takeda","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00262-018-2228-7","article-title":"T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient","volume":"67","author":"Wieland","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00262-014-1605-0","article-title":"Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome","volume":"63","author":"Foureau","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2023031315400027500_","first-page":"680","article-title":"High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?","volume":"27","author":"Amin","year":"2013","journal-title":"Oncology"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.soc.2011.01.010","article-title":"Cancer immunotherapy","volume":"20","author":"White","year":"2011","journal-title":"Surg Oncol Clin N Am"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1093\/bioinformatics\/bti681","article-title":"Classification of microarrays to nearest centroids","volume":"21","author":"Dabney","year":"2005","journal-title":"Bioinformatics"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jtho.2017.03.010","article-title":"Lung adenocarcinoma and squamous cell carcinoma gene expression subtypes demonstrate significant differences in tumor immune landscape","volume":"12","author":"Faruki","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.eururo.2014.02.035","article-title":"ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma","volume":"66","author":"Brooks","year":"2014","journal-title":"Eur Urol"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"Mcdermott","year":"2018","journal-title":"Nat Med"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1947601909359929","article-title":"Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns","volume":"1","author":"Brannon","year":"2010","journal-title":"Genes Cancer"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"e1049804","DOI":"10.1080\/2162402X.2015.1049804","article-title":"Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)","volume":"4","author":"Becht","year":"2015","journal-title":"Oncoimmunology"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/2159-8290.CD-17-1246","article-title":"An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors","volume":"8","author":"Wang","year":"2018","journal-title":"Cancer Discov"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/CCO.0000000000000512","article-title":"The tumor microenvironment in renal cell cancer","volume":"31","author":"Mier","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00428-016-1973-2","article-title":"Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma","volume":"469","author":"Cros","year":"2016","journal-title":"Virchows Arch"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamaoncol.2019.1549","article-title":"Comparison of biomarker modalities for predicting response to PD-1\/PD-L1 checkpoint blockade: a systematic review and meta-analysis","volume":"5","author":"Lu","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"S678","DOI":"10.1016\/j.annonc.2021.08.057","article-title":"661P conditional survival and 5-year follow-up in CheckMate 214: first-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)","volume":"32","author":"Motzer","year":"2021","journal-title":"Ann Oncol"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.2147\/CMAR.S202017","article-title":"Ipilimumab and nivolumab as first-line treatment of patients with renal cell carcinoma: the evidence to date","volume":"12","author":"Sheng","year":"2020","journal-title":"Cancer Manag Res"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-15-1631","article-title":"NKTR-214, an engineered cytokine with biased il2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models","volume":"22","author":"Charych","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/cas.13842","article-title":"Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma","volume":"110","author":"Zhang","year":"2019","journal-title":"Cancer Sci"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.3389\/fimmu.2018.03120","article-title":"The evolving landscape of immunotherapy-based combinations for frontline treatment of advanced renal cell carcinoma","volume":"9","author":"Amin","year":"2019","journal-title":"Front Immunol"},{"key":"2023031315400027500_","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/archotol.1990.01870110074009","article-title":"The in vivo biologic effect of interleukin 2 and interferon alfa on natural immunity in patients with head and neck cancer","volume":"116","author":"Schantz","year":"1990","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2023031315400027500_","first-page":"A446","article-title":"420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study","volume":"8","author":"Diab","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-21-0153\/3181866\/crc-21-0153.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/8\/894\/3282552\/crc-21-0153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/8\/894\/3282552\/crc-21-0153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T18:07:08Z","timestamp":1700849228000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/8\/894\/708816\/Distinct-Predictive-Immunogenomic-Profiles-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,30]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-21-0153","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6550872","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545180.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550872.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545183.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545180","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545183","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]}}}